Histone demethylase inhibitors
AssigneeQuanticel Pharmaceuticals, Inc.
InventorsYoung K. Chen, Toufike Kanouni, Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
Claims21
A compound of Formula (XI), or a pharmaceutically acceptable salt thereof,
- wherein:
- Q is —CO2R, —C(O)N(H)CN, —C(O)N(H)OH, or tetrazolyl;
- R is hydrogen or optionally substituted alkyl;
- G is —X—Y;
- X is —C1 alkylene;
- Y is optionally substituted tetralinyl, optionally substituted tetrahydroquinolinyl, substituted pyridyl, optionally substituted naphthyl, optionally substituted indolyl, optionally substituted benzofuranyl, optionally substituted adamantyl, or optionally substituted indanyl.
A compound of Formula (XI), or a pharmaceutically acceptable salt thereof,
- wherein:
- Q is —CO2R, —C(O)N(H)CN, —C(O)N(H)OH, or tetrazolyl;
- R is hydrogen or optionally substituted alkyl;
- G is —X—Y;
- X is —C1 alkylene;
- Y is phenyl substituted with alkenyl, alkynyl, fluoro, chloro, fluoroalkyl, nitro, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, —Rb—ORa, —Rb—OC(O)—Ra, —Rb—OC(O)—ORa, —Rb—OC(O)—N(Ra)2, —Rb—N(Ra)2, —Rb—C(O)Ra, —Rb—C(O)ORa, —Rb—O—Rc—C(O)N(Ra)2, —Rb—N(Ra)C(O)ORa, —Rb—N(Ra)C(O)Ra, —Rb—N(Ra)S(O)tRa, —Rb—S(O)tORa, —Rb—S(O)tORa, and —Rb—S(O)tN(Ra)2;
- wherein:
- each Ra is independently hydrogen, alkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
- each Rb is independently a direct bond or a straight or branched alkylene or alkenylene chain;
- each Rc is a straight or branched alkylene or alkenylene chain;
- and
- t is 1 or 2.
A compound of Formula (XV), or a pharmaceutically acceptable salt thereof,
- wherein,
- Q is —CO2R, —C(O)N(H)CN, —C(O)N(H)OH, or tetrazolyl;
- R is hydrogen or optionally substituted alkyl;
- G is —X—Y;
- X is —C1 alkylene;
- Y is carbocyclyl, heterocyclyl, aryl, or heteroaryl;
- with the provisio that G is not
(canceled)
A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
Dependencies are inferred from the claim text.